{"id":2180,"date":"2026-11-09T17:57:48","date_gmt":"2026-11-09T16:57:48","guid":{"rendered":"https:\/\/doktorpeptid.sk\/retatrutid-triumph-1-pokles-hmotnosti\/"},"modified":"2026-11-09T17:57:48","modified_gmt":"2026-11-09T16:57:48","slug":"retatrutid-triumph-1-pokles-hmotnosti","status":"publish","type":"post","link":"https:\/\/doktorpeptid.sk\/en\/retatrutid-triumph-1-pokles-hmotnosti\/","title":{"rendered":"Retatrutid: najv\u00e4\u010d\u0161\u00ed pokles hmotnosti v \u0161t\u00fadii TRIUMPH-1"},"content":{"rendered":"<style>\n.dp-lead{font-size:1.15em;line-height:1.7;color:#1b2440}\n.dp-note{background:#f3f6ff;border:1px solid #d9e2ff;border-left:4px solid #1f5bff;border-radius:12px;padding:16px 20px;margin:24px 0;font-size:.95em;color:#24304f}\n.dp-note--end{border-left-color:#ff4d5e;background:#fff5f6;border-color:#ffd9de}\n.dp-table-wrap{overflow-x:auto;margin:20px 0 28px;border:1px solid #e3e8f2;border-radius:14px}\n.dp-table{width:100%;border-collapse:collapse;font-size:.95em;margin:0}\n.dp-table th{background:#0b1530;color:#fff;text-align:left;padding:12px 14px;font-weight:700}\n.dp-table th:nth-child(2){color:#7fd6ff}.dp-table th:nth-child(3){color:#ffc56b}\n.dp-table td{padding:11px 14px;border-top:1px solid #e9edf5;vertical-align:top}\n.dp-table td:first-child{font-weight:700;color:#1b2440;white-space:nowrap;background:#f8faff}\n.dp-fig{margin:28px auto;text-align:center}\n.dp-fig img{border-radius:16px;max-width:100%;height:auto;box-shadow:0 12px 40px rgba(11,21,48,.18)}\n.dp-fig--formula img{background:#fff;padding:18px;box-shadow:none;border:1px solid #e3e8f2;max-height:420px;width:auto}\n.dp-fig figcaption{font-size:.85em;color:#6b7690;margin-top:10px}\n.dp-cards{display:grid;grid-template-columns:repeat(auto-fit,minmax(220px,1fr));gap:16px;margin:20px 0}\n.dp-card{border-radius:16px;padding:20px 22px;color:#fff}\n.dp-card p{margin:8px 0 0;color:rgba(255,255,255,.88);font-size:.95em}\n.dp-card--blue{background:linear-gradient(135deg,#0b2a6b,#1f5bff)}.dp-card--gold{background:linear-gradient(135deg,#5a3200,#d98a12)}\n.dp-card__k{font-size:.8em;letter-spacing:.12em;text-transform:uppercase;opacity:.8}.dp-card__t{font-size:1.35em;font-weight:800;margin-top:2px}\n.dp-product{display:grid;grid-template-columns:repeat(auto-fit,minmax(180px,1fr));gap:12px;margin:22px 0}\n.dp-product__card{display:flex;flex-direction:column;gap:4px;padding:16px 18px;border:1px solid #dfe5f1;border-radius:14px;text-decoration:none!important;color:#0b1530!important;transition:.2s}\n.dp-product__card:hover{border-color:#1f5bff;box-shadow:0 8px 24px rgba(31,91,255,.15);transform:translateY(-2px)}\n.dp-product__k{font-size:.75em;text-transform:uppercase;letter-spacing:.1em;color:#1f5bff;font-weight:700}.dp-product__t{font-weight:800}.dp-product__s{font-size:.85em;color:#6b7690}\n.dp-sources{font-size:.88em;color:#46506a}.dp-sources li{margin-bottom:6px}\n.dp-product br,.dp-cards br{display:none}\n<\/style>\n<p class=\"dp-lead\">V novembri 2026 vy\u0161li v \u010dasopise <em>New England Journal of Medicine<\/em> v\u00fdsledky \u0161t\u00fadie <strong>TRIUMPH-1<\/strong>, prvej ve\u013ekej \u0161t\u00fadie f\u00e1zy 3 s retatrutidom pri obezite. Ide o najv\u00e4\u010d\u0161\u00ed pokles hmotnosti, ak\u00fd bol doteraz pri lieku v klinickej \u0161t\u00fadii hl\u00e1sen\u00fd. V \u010dl\u00e1nku prech\u00e1dzame \u010d\u00edsla, porovnanie so star\u0161\u00edmi l\u00e1tkami aj ved\u013eaj\u0161ie \u00fa\u010dinky.<\/p>\n<h2>\u010co je TRIUMPH-1<\/h2>\n<p>TRIUMPH-1 (NCT05929066) je randomizovan\u00e1, dvojito zaslepen\u00e1 \u0161t\u00fadia kontrolovan\u00e1 placebom. Z\u00fa\u010dastnilo sa jej <strong>2 339 dospel\u00fdch<\/strong> s obezitou alebo nadv\u00e1hou a aspo\u0148 jedn\u00fdm pridru\u017een\u00fdm ochoren\u00edm, bez cukrovky. \u00da\u010dastn\u00edci boli rozdelen\u00ed do \u0161tyroch skup\u00edn: tri skupiny s r\u00f4znymi d\u00e1vkami retatrutidu (n\u00edzkou, strednou a najvy\u0161\u0161ou) a placebo. Hlavn\u00e1 f\u00e1za trvala <strong>80 t\u00fd\u017ed\u0148ov<\/strong>. Priemern\u00e1 hmotnos\u0165 na za\u010diatku bola 112,7 kg a priemern\u00e9 BMI 40.<\/p>\n<p>Retatrutid je syntetick\u00fd peptid, ktor\u00fd naraz aktivuje tri receptory: pre <strong>GLP-1, GIP a glukag\u00f3n<\/strong>. Preto sa mu hovor\u00ed trojit\u00fd agonista. Podrobnej\u0161ie o mechanizme a o v\u00fdsledkoch pri pe\u010deni, kolen\u00e1ch a sp\u00e1nku sme p\u00edsali v \u010dl\u00e1nku <a href=\"\/en\/retatrutid-pecen-kolena-spanok-studie\/\">Retatrutid: pe\u010de\u0148, kolen\u00e1 a sp\u00e1nok<\/a>.<\/p>\n<figure class=\"dp-fig\"><img decoding=\"async\" src=\"https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-1024x1024.jpg\" alt=\"Jedna molekula a tri hormon\u00e1lne receptory \u2013 ilustr\u00e1cia\" width=\"1024\" height=\"1024\" class=\"wp-image-2177 size-large\" loading=\"lazy\" title=\"Retatrutid: najv\u00e4\u010d\u0161\u00ed pokles hmotnosti v \u0161t\u00fadii TRIUMPH-1\" srcset=\"https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-1024x1024.jpg 1024w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-300x300.jpg 300w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-150x150.jpg 150w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-768x768.jpg 768w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-12x12.jpg 12w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-700x700.jpg 700w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-600x600.jpg 600w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-1200x1200.jpg 1200w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia-100x100.jpg 100w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-tri-hormony-ilustracia.jpg 1254w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption>Ilustr\u00e1cia: tri hormon\u00e1lne receptory a jedna molekula.<\/figcaption><\/figure>\n<h2>V\u00fdsledky: o ko\u013eko klesla hmotnos\u0165<\/h2>\n<p>\u0160t\u00fadia hl\u00e1si v\u00fdsledky dvoma sp\u00f4sobmi. Prv\u00fd (tzv. <em>treatment-regimen estimand<\/em>, publikovan\u00fd v NEJM) zapo\u010d\u00edtava v\u0161etk\u00fdch \u00fa\u010dastn\u00edkov bez oh\u013eadu na to, \u010di lie\u010dbu dodr\u017eali. Druh\u00fd (tzv. <em>efficacy estimand<\/em> z tla\u010dovej spr\u00e1vy Lilly) ukazuje \u00fa\u010dinok u t\u00fdch, ktor\u00ed lie\u010dbu u\u017e\u00edvali pod\u013ea pl\u00e1nu.<\/p>\n<div class=\"dp-table-wrap\">\n<table class=\"dp-table\">\n<thead>\n<tr>\n<th>Skupina<\/th>\n<th>Pokles hmotnosti (v\u0161etci, NEJM)<\/th>\n<th>Pokles pri dodr\u017ean\u00ed lie\u010dby<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Najni\u017e\u0161ia d\u00e1vka<\/td>\n<td>\u221217,6 %<\/td>\n<td>\u221219,0 % (\u221221,4 kg)<\/td>\n<\/tr>\n<tr>\n<td>Stredn\u00e1 d\u00e1vka<\/td>\n<td>\u221223,7 %<\/td>\n<td>\u221225,9 % (\u221229,2 kg)<\/td>\n<\/tr>\n<tr>\n<td>Najvy\u0161\u0161ia d\u00e1vka<\/td>\n<td>\u221225,0 %<\/td>\n<td>\u221228,3 % (\u221231,9 kg)<\/td>\n<\/tr>\n<tr>\n<td>Placebo<\/td>\n<td>\u22123,9 %<\/td>\n<td>\u22122,2 % (\u22122,5 kg)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pri najvy\u0161\u0161ej d\u00e1vke schudlo aspo\u0148 30 % hmotnosti <strong>45,3 %<\/strong> \u00fa\u010dastn\u00edkov. Tak\u00fdto pokles sa doteraz sp\u00e1jal najm\u00e4 s bariatrick\u00fdmi oper\u00e1ciami. Obvod p\u00e1sa klesol v priemere o <strong>24,1 cm<\/strong> a <strong>65,3 %<\/strong> \u00fa\u010dastn\u00edkov sa dostalo pod hranicu obezity (BMI pod 30).<\/p>\n<p>V pred\u013a\u017een\u00ed \u0161t\u00fadie na 104 t\u00fd\u017ed\u0148ov (532 \u00fa\u010dastn\u00edkov s BMI 35 a viac) pokra\u010doval pokles a\u017e na <strong>\u221230,3 %<\/strong>. Zlep\u0161ili sa aj \u010fal\u0161ie ukazovatele: krvn\u00fd tlak, triglyceridy, non-HDL cholesterol aj z\u00e1palov\u00fd marker hsCRP.<\/p>\n<figure class=\"dp-fig\"><img decoding=\"async\" src=\"https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-1024x1024.jpg\" alt=\"Pokles hmotnosti v \u0161t\u00fadii TRIUMPH-1 pod\u013ea d\u00e1vky \u2013 graf\" width=\"1024\" height=\"1024\" class=\"wp-image-2178 size-large\" loading=\"lazy\" title=\"Retatrutid: najv\u00e4\u010d\u0161\u00ed pokles hmotnosti v \u0161t\u00fadii TRIUMPH-1\" srcset=\"https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-1024x1024.jpg 1024w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-300x300.jpg 300w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-150x150.jpg 150w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-768x768.jpg 768w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-12x12.jpg 12w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-700x700.jpg 700w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-600x600.jpg 600w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf-100x100.jpg 100w, https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-pokles-hmotnosti-graf.jpg 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption>Ilustr\u00e1cia: pokles hmotnosti v jednotliv\u00fdch skupin\u00e1ch za 80 t\u00fd\u017ed\u0148ov.<\/figcaption><\/figure>\n<h2>Kolen\u00e1 a sp\u00e1nok v tej istej \u0161t\u00fadii<\/h2>\n<p>TRIUMPH-1 mala aj dve podskupiny. U <strong>574 \u00fa\u010dastn\u00edkov s artr\u00f3zou kolena<\/strong> klesla boles\u0165 (sk\u00f3re WOMAC) v\u00fdraznej\u0161ie ako na placebe. U <strong>243 \u00fa\u010dastn\u00edkov so sp\u00e1nkov\u00fdm apnoe<\/strong> ubudlo pri strednej d\u00e1vke v priemere 34 preru\u0161en\u00ed d\u00fdchania za hodinu, na placebe asi 10.<\/p>\n<h2>Porovnanie so star\u0161\u00edmi l\u00e1tkami<\/h2>\n<p>Priame porovnanie v jednej \u0161t\u00fadii zatia\u013e neexistuje, no orienta\u010dne pom\u00f4\u017eu v\u00fdsledky podobne navrhnut\u00fdch \u0161t\u00fadi\u00ed (v\u0161etci \u00fa\u010dastn\u00edci, najvy\u0161\u0161ia d\u00e1vka):<\/p>\n<div class=\"dp-table-wrap\">\n<table class=\"dp-table\">\n<thead>\n<tr>\n<th>L\u00e1tka<\/th>\n<th>Receptory<\/th>\n<th>\u0160t\u00fadia<\/th>\n<th>Pokles hmotnosti<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Semaglutid<\/td>\n<td>GLP-1<\/td>\n<td>STEP 1, 68 t\u00fd\u017ed\u0148ov<\/td>\n<td>\u221214,9 %<\/td>\n<\/tr>\n<tr>\n<td>Tirzepatid<\/td>\n<td>GLP-1 + GIP<\/td>\n<td>SURMOUNT-1, 72 t\u00fd\u017ed\u0148ov<\/td>\n<td>\u221220,9 %<\/td>\n<\/tr>\n<tr>\n<td>Retatrutid<\/td>\n<td>GLP-1 + GIP + glukag\u00f3n<\/td>\n<td>TRIUMPH-1, 80 t\u00fd\u017ed\u0148ov<\/td>\n<td>\u221225,0 %<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\u0160t\u00fadie sa l\u00ed\u0161ia d\u013a\u017ekou, popul\u00e1ciou aj sp\u00f4sobom vyhodnotenia, preto ide len o hrub\u00e9 porovnanie.<\/p>\n<h2>Ved\u013eaj\u0161ie \u00fa\u010dinky<\/h2>\n<p>Naj\u010dastej\u0161ie boli tr\u00e1viace \u0165a\u017ekosti, podobne ako pri in\u00fdch l\u00e1tkach z tejto skupiny. Pri najvy\u0161\u0161ej d\u00e1vke hl\u00e1silo nevo\u013enos\u0165 42,4 % \u00fa\u010dastn\u00edkov (placebo 14,8 %), hna\u010dku 32,0 %, z\u00e1pchu 26,1 % a vracanie 25,3 %. \u010castej\u0161ie sa objavovala aj dyzest\u00e9zia (nepr\u00edjemn\u00e9 vn\u00edmanie dotyku na ko\u017ei), u 12,5 % oproti 0,9 % na placebe. Pre ved\u013eaj\u0161ie \u00fa\u010dinky ukon\u010dilo \u0161t\u00fadiu 11,3 % \u00fa\u010dastn\u00edkov s najvy\u0161\u0161ou d\u00e1vkou a 4,9 % na placebe.<\/p>\n<div class=\"dp-product\"><a class=\"dp-product__card\" href=\"\/en\/product\/retatrutide\/\"><span class=\"dp-product__k\">V\u00fdskumn\u00fd peptid<\/span><span class=\"dp-product__t\">Retatrutide<\/span><span class=\"dp-product__s\">iba na v\u00fdskum<\/span><\/a><a class=\"dp-product__card\" href=\"\/en\/retatrutid-pecen-kolena-spanok-studie\/\"><span class=\"dp-product__k\">\u010cl\u00e1nok<\/span><span class=\"dp-product__t\">Pe\u010de\u0148, kolen\u00e1, sp\u00e1nok<\/span><span class=\"dp-product__s\">\u010fal\u0161ie \u0161t\u00fadie<\/span><\/a><a class=\"dp-product__card\" href=\"\/en\/coa\/\"><span class=\"dp-product__k\">Documents<\/span><span class=\"dp-product__t\">COA certifik\u00e1ty<\/span><span class=\"dp-product__s\">nez\u00e1visl\u00e9 testy \u0161ar\u017e\u00ed<\/span><\/a><\/div>\n<h2>Frequently asked questions<\/h2>\n<h3>Je retatrutid schv\u00e1len\u00fd liek?<\/h3>\n<p>Nie. Retatrutid je st\u00e1le sk\u00faman\u00e1 l\u00e1tka v klinick\u00fdch \u0161t\u00fadi\u00e1ch spolo\u010dnosti Eli Lilly. \u010eal\u0161ie \u0161t\u00fadie f\u00e1zy 3 (TRIUMPH-2, TRIUMPH-3 a TRIUMPH-Outcomes) e\u0161te prebiehaj\u00fa.<\/p>\n<h3>Pre\u010do sa v\u00fdsledky l\u00ed\u0161ia (25,0 % vs. 28,3 %)?<\/h3>\n<p>Ide o dva sp\u00f4soby vyhodnotenia. Ni\u017e\u0161ie \u010d\u00edslo zah\u0155\u0148a aj \u013eud\u00ed, ktor\u00ed lie\u010dbu preru\u0161ili, vy\u0161\u0161ie ukazuje \u00fa\u010dinok pri dodr\u017ean\u00ed lie\u010dby pod\u013ea pl\u00e1nu.<\/p>\n<h3>\u010co znamen\u00e1 \u201etrojit\u00fd agonista\u201c?<\/h3>\n<p>Jedna molekula aktivuje tri r\u00f4zne receptory: pre GLP-1, GIP a glukag\u00f3n.<\/p>\n<h2>Zdroje<\/h2>\n<ol class=\"dp-sources\">\n<li>Jastreboff A. M. a kol. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. <em>N Engl J Med<\/em>, 2026. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42814954\/\" target=\"_blank\" rel=\"noopener\">PubMed 42814954<\/a><\/li>\n<li>Eli Lilly: v\u00fdsledky \u0161t\u00fadie TRIUMPH-1 (m\u00e1j 2026). <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" target=\"_blank\" rel=\"noopener\">investor.lilly.com<\/a><\/li>\n<li>Wilding J. P. H. a kol. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). <em>N Engl J Med<\/em>, 2021. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33567185\/\" target=\"_blank\" rel=\"noopener\">PubMed 33567185<\/a><\/li>\n<li>Jastreboff A. M. a kol. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). <em>N Engl J Med<\/em>, 2022. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\" target=\"_blank\" rel=\"noopener\">PubMed 35658024<\/a><\/li>\n<li>TRIUMPH-1, <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov NCT05929066<\/a><\/li>\n<\/ol>\n<div class=\"dp-note dp-note--end\">\u010cl\u00e1nok m\u00e1 eduka\u010dn\u00fd charakter a nepredstavuje zdravotn\u00fa radu. Produkty DoktorPeptid s\u00fa ur\u010den\u00e9 v\u00fdhradne na vedeck\u00e9 a laborat\u00f3rne \u00fa\u010dely.<\/div>","protected":false},"excerpt":{"rendered":"<p>V \u0161t\u00fadii f\u00e1zy 3 TRIUMPH-1 schudli \u00fa\u010dastn\u00edci na najvy\u0161\u0161ej d\u00e1vke retatrutidu v priemere 25 %. Prech\u00e1dzame \u010d\u00edsla, porovnanie so semaglutidom a tirzepatidom aj ved\u013eaj\u0161ie \u00fa\u010dinky.<\/p>","protected":false},"author":1,"featured_media":2179,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[102],"tags":[],"class_list":["post-2180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptidy-vo-vyskume"],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/doktorpeptid.sk\/wp-content\/uploads\/2026\/11\/retatrutide-triumph1-doktorpeptid.jpg","_links":{"self":[{"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/posts\/2180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/comments?post=2180"}],"version-history":[{"count":0,"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/posts\/2180\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/media\/2179"}],"wp:attachment":[{"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/media?parent=2180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/categories?post=2180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/doktorpeptid.sk\/en\/wp-json\/wp\/v2\/tags?post=2180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}